FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B

Royalty Pharma plc

Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.
Long-term capital of $225M fully drawn; launch capital of $225M with $50M drawn to date.
Royalty Pharma to receive $523M in quarterly repayments over 10 years (1.9x); $20M repaid through Sep 2025.
Following approval, Cytokinetics can draw additional $175M within 12 months, repayable at 1.9x over 10 years.
MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.